A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19.
Huo J, Mikolajek H, Le Bas A, Clark JJ, Sharma P, Kipar A, Dormon J, Norman C, Weckener M, Clare DK, Harrison PJ, Tree JA, Buttigieg KR, Salguero FJ, Watson R, Knott D, Carnell O, Ngabo D, Elmore MJ, Fotheringham S, Harding A, Moynie L, Ward PN, Dumoux M, Prince T, Hall Y, Hiscox JA, Owen A, James W, Carroll MW, Stewart JP, Naismith JH, Owens RJ
Nat Commun. 2021 Sep 22;12(1):5469. doi: 10.1038/s41467-021-25480-z.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 171924 | pOPINO_C1 | Bacterial expression of nanobody VHH_C1, which binds to receptor binding domain of the spike protein of SARS-CoV-2 |
| 171925 | pOPINO_C5 | Bacterial expression of nanobody VHH_C5, which binds to receptor binding domain of the spike protein of SARS-CoV-2 |
| 171926 | pOPINO_F2 | Bacterial expression of nanobody VHH_F2, which binds to receptor binding domain of the spike protein of SARS-CoV-2 |
| 171927 | pOPINO_H3 | Bacterial expression of nanobody VHH_H3, which binds to receptor binding domain of the spike protein of SARS-CoV-2 |